Co-transplantation of MSC in the Setting of Allo-HSCT

Last updated: January 29, 2020
Sponsor: Fujian Medical University
Overall Status: Active - Recruiting

Phase

2/3

Condition

Allogeneic Hematopoietic Stem Cell Transplant

Allo-hematopoietic Stem Cell Transplant

Treatment

N/A

Clinical Study ID

NCT04247945
MSC-SCT-03
  • Ages < 65
  • All Genders

Study Summary

Mesenchymal stem cells (MSCs) are known to exhibit immunomodulatory, anti-inflammatory, and pro-angiogenic properties, and therefore have the potential to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) .The study is aimed to identify and evaluate the potential benefits of MSCs infusion during allogeneic HSCT, with regard to the engraftment, graft versus host disease (GVHD), post-transplant relapse and survival.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Signed written informed consent

  • Aged <65 years

  • Willing to transplant

  • Cardiac: Left ventricular ejection fraction ≥ 50%

  • Adequate renal and hepatic function

  • Performance status: Karnofsky ≥ 70%

Exclusion

Exclusion Criteria:

  • Pregnant or lactating females.

  • Any co-morbidity precluding the administration of MSCs.

Study Design

Total Participants: 120
Study Start date:
February 01, 2020
Estimated Completion Date:
December 01, 2025

Connect with a study center

  • Union Hospital,Fujian Medical University

    Fuzhou, Fujian 350001
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.